Avanos Medical, Inc. (NYSE: AVNS) reported Q3 EPS of $0.36, $0.01 better than the analyst estimate of $0.35. Revenue for the quarter came in at $170.4 million versus the consensus estimate of $175.2 million.

GUIDANCE:

Avanos Medical, Inc. sees FY2024 EPS of $1.30-$1.35, versus the consensus of $1.39. Avanos Medical, Inc. sees FY2024 revenue of $683-688 million, versus the consensus of $695.3 million.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.